Publicação
Epidemic history and baseline resistance to NS5A-specific direct acting drugs of hepatitis C virus in Spain
| Resumo: | Hepatitis C virus (HCV) infection remains a global health problem. Previously, the prevalence of NS5A resistance-associated substitutions (RASs) to elbasvir, a new direct-acting antiviral (DAA) against the NS5A viral protein was assessed by our group before its introduction into clinical use in Spain. However, the origin, epidemic history, transmission dynamics, diversity and baseline RASs to NS5A direct-acting agents of HCV-GT1a in Spain remain unknown. A nationwide cross-sectional survey of individuals chronically-infected with HCV-G1a and DAAs-naïve was performed. HCV population sequencing, phylogenetic analysis and Bayesian methods were used. GT1a clade II was more prevalent than clade I (82.3% vs. 17.7%; P < 0.001) and older (estimated origin in 1912 vs. 1952). Clade II epidemic is currently declining whereas clade I epidemic has reached equilibrium. A total of 58 single RASs were identified, which account for the moderate level (10%) of baseline resistance observed. When considering the regional data, marked differences were observed, with thirteen regions showing an intermediate level (5–15%) and one a high level (20%) of resistance. Current HCV-GT1a epidemic in Spain is driven by clade I which seem to have different dissemination routes relative to clade II. A moderate level of baseline RASs to NS5A-DAAs with marked differences among regions was observed. Close surveillance of response to treatment with DAAs will be important. |
|---|---|
| Autores principais: | Palladino, Claudia |
| Outros Autores: | Ezeonwumelu, Ifeanyi J.; Maté, Irene; Borrego, Pedro; Martínez-Román, Paula; Arca-Lafuente, Sonia; Resino, Salvador; Taveira, Nuno; Briz, Verónica |
| Ano: | 2020 |
| País: | Portugal |
| Tipo de documento: | artigo |
| Tipo de acesso: | acesso aberto |
| Instituição associada: | Universidade de Lisboa |
| Idioma: | inglês |
| Origem: | Repositório da Universidade de Lisboa |
| _version_ | 1866811473729159168 |
|---|---|
| author | Palladino, Claudia |
| author2 | Ezeonwumelu, Ifeanyi J. Maté, Irene Borrego, Pedro Martínez-Román, Paula Arca-Lafuente, Sonia Resino, Salvador Taveira, Nuno Briz, Verónica |
| author2_role | author author author author author author author author |
| author_facet | Palladino, Claudia Ezeonwumelu, Ifeanyi J. Maté, Irene Borrego, Pedro Martínez-Román, Paula Arca-Lafuente, Sonia Resino, Salvador Taveira, Nuno Briz, Verónica |
| author_role | author |
| contributor_name_str_mv | Repositório Científico de Acesso Aberto da ULisboa |
| country_str | PT |
| creators_json_txt | [{\"Person.name\":\"Palladino, Claudia\",\"Person.identifier.orcid\":\"0000-0002-8148-0928\"},{\"Person.name\":\"Ezeonwumelu, Ifeanyi J.\",\"Person.identifier.orcid\":\"0000-0003-4007-2212\"},{\"Person.name\":\"Maté, Irene\",\"Person.identifier.orcid\":\"0000-0002-9045-9581\"},{\"Person.name\":\"Borrego, Pedro\",\"Person.identifier.orcid\":\"0000-0002-1949-9484\"},{\"Person.name\":\"Martínez-Román, Paula\"},{\"Person.name\":\"Arca-Lafuente, Sonia\",\"Person.identifier.orcid\":\"0000-0003-4750-0988\"},{\"Person.name\":\"Resino, Salvador\",\"Person.identifier.orcid\":\"0000-0001-8783-0450\"},{\"Person.name\":\"Taveira, Nuno\",\"Person.identifier.orcid\":\"0000-0003-0176-5585\"},{\"Person.name\":\"Briz, Verónica\",\"Person.identifier.orcid\":\"0000-0003-2297-5098\"}] |
| datacite.contributors.contributor.contributorName.fl_str_mv | Repositório Científico de Acesso Aberto da ULisboa |
| datacite.creators.creator.creatorName.fl_str_mv | Palladino, Claudia Ezeonwumelu, Ifeanyi J. Maté, Irene Borrego, Pedro Martínez-Román, Paula Arca-Lafuente, Sonia Resino, Salvador Taveira, Nuno Briz, Verónica |
| datacite.date.Accepted.fl_str_mv | 2020-12-01T00:00:00Z |
| datacite.date.available.fl_str_mv | 2023-08-31T13:35:52Z |
| datacite.date.embargoed.fl_str_mv | 2023-08-31T13:35:52Z |
| datacite.rights.fl_str_mv | http://purl.org/coar/access_right/c_abf2 |
| datacite.titles.title.fl_str_mv | Epidemic history and baseline resistance to NS5A-specific direct acting drugs of hepatitis C virus in Spain |
| dc.contributor.none.fl_str_mv | Repositório Científico de Acesso Aberto da ULisboa |
| dc.creator.none.fl_str_mv | Palladino, Claudia Ezeonwumelu, Ifeanyi J. Maté, Irene Borrego, Pedro Martínez-Román, Paula Arca-Lafuente, Sonia Resino, Salvador Taveira, Nuno Briz, Verónica |
| dc.date.Accepted.fl_str_mv | 2020-12-01T00:00:00Z |
| dc.date.available.fl_str_mv | 2023-08-31T13:35:52Z |
| dc.date.embargoed.fl_str_mv | 2023-08-31T13:35:52Z |
| dc.format.none.fl_str_mv | application/pdf |
| dc.identifier.none.fl_str_mv | http://hdl.handle.net/10451/59104 |
| dc.language.none.fl_str_mv | eng |
| dc.publisher.none.fl_str_mv | Springer Nature |
| dc.rights.cclincense.fl_str_mv | http://creativecommons.org/licenses/by/4.0/ |
| dc.rights.none.fl_str_mv | http://purl.org/coar/access_right/c_abf2 |
| dc.title.fl_str_mv | Epidemic history and baseline resistance to NS5A-specific direct acting drugs of hepatitis C virus in Spain |
| dc.type.none.fl_str_mv | http://purl.org/coar/resource_type/c_6501 |
| description | Hepatitis C virus (HCV) infection remains a global health problem. Previously, the prevalence of NS5A resistance-associated substitutions (RASs) to elbasvir, a new direct-acting antiviral (DAA) against the NS5A viral protein was assessed by our group before its introduction into clinical use in Spain. However, the origin, epidemic history, transmission dynamics, diversity and baseline RASs to NS5A direct-acting agents of HCV-GT1a in Spain remain unknown. A nationwide cross-sectional survey of individuals chronically-infected with HCV-G1a and DAAs-naïve was performed. HCV population sequencing, phylogenetic analysis and Bayesian methods were used. GT1a clade II was more prevalent than clade I (82.3% vs. 17.7%; P < 0.001) and older (estimated origin in 1912 vs. 1952). Clade II epidemic is currently declining whereas clade I epidemic has reached equilibrium. A total of 58 single RASs were identified, which account for the moderate level (10%) of baseline resistance observed. When considering the regional data, marked differences were observed, with thirteen regions showing an intermediate level (5–15%) and one a high level (20%) of resistance. Current HCV-GT1a epidemic in Spain is driven by clade I which seem to have different dissemination routes relative to clade II. A moderate level of baseline RASs to NS5A-DAAs with marked differences among regions was observed. Close surveillance of response to treatment with DAAs will be important. |
| dirty | 0 |
| eu_rights_str_mv | openAccess |
| format | article |
| fulltext.url.fl_str_mv | https://repositorio.ulisboa.pt/bitstreams/f2090f69-c5e5-4243-8a89-2bb71bb2f816/download |
| id | ul_4570888fe73c2e91433aa71f6ae2dad1 |
| identifier.url.fl_str_mv | http://hdl.handle.net/10451/59104 |
| instacron_str | ul |
| institution | Universidade de Lisboa |
| instname_str | Universidade de Lisboa |
| language | eng |
| network_acronym_str | ul |
| network_name_str | Repositório da Universidade de Lisboa |
| oai_identifier_str | oai:repositorio.ulisboa.pt:10451/59104 |
| organization_str_mv | urn:organizationAcronym:ul |
| person_str_mv | Palladino, Claudia Palladino, Claudia https://www.ciencia-id.pt/721D-6851-20D5 721D-6851-20D5 http://orcid.org/0000-0002-8148-0928 0000-0002-8148-0928 Ezeonwumelu, Ifeanyi J. Ezeonwumelu, Ifeanyi J. http://orcid.org/0000-0003-4007-2212 0000-0003-4007-2212 Maté, Irene Maté, Irene http://orcid.org/0000-0002-9045-9581 0000-0002-9045-9581 Borrego, Pedro Borrego, Pedro https://www.ciencia-id.pt/A71C-0177-722F A71C-0177-722F http://orcid.org/0000-0002-1949-9484 0000-0002-1949-9484 Martínez-Román, Paula Arca-Lafuente, Sonia Arca-Lafuente, Sonia http://orcid.org/0000-0003-4750-0988 0000-0003-4750-0988 Resino, Salvador Resino, Salvador http://orcid.org/0000-0001-8783-0450 0000-0001-8783-0450 Taveira, Nuno Taveira, Nuno https://www.ciencia-id.pt/7111-3383-A926 7111-3383-A926 http://orcid.org/0000-0003-0176-5585 0000-0003-0176-5585 Briz, Verónica Briz, Verónica http://orcid.org/0000-0003-2297-5098 0000-0003-2297-5098 |
| publishDate | 2020 |
| publisher.none.fl_str_mv | Springer Nature |
| reponame_str | Repositório da Universidade de Lisboa |
| repository_id_str | urn:repositoryAcronym:ul |
| service_str_mv | urn:repositoryAcronym:ul |
| spelling | engSpringer Naturept_PTHepatitis C virus (HCV) infection remains a global health problem. Previously, the prevalence of NS5A resistance-associated substitutions (RASs) to elbasvir, a new direct-acting antiviral (DAA) against the NS5A viral protein was assessed by our group before its introduction into clinical use in Spain. However, the origin, epidemic history, transmission dynamics, diversity and baseline RASs to NS5A direct-acting agents of HCV-GT1a in Spain remain unknown. A nationwide cross-sectional survey of individuals chronically-infected with HCV-G1a and DAAs-naïve was performed. HCV population sequencing, phylogenetic analysis and Bayesian methods were used. GT1a clade II was more prevalent than clade I (82.3% vs. 17.7%; P < 0.001) and older (estimated origin in 1912 vs. 1952). Clade II epidemic is currently declining whereas clade I epidemic has reached equilibrium. A total of 58 single RASs were identified, which account for the moderate level (10%) of baseline resistance observed. When considering the regional data, marked differences were observed, with thirteen regions showing an intermediate level (5–15%) and one a high level (20%) of resistance. Current HCV-GT1a epidemic in Spain is driven by clade I which seem to have different dissemination routes relative to clade II. A moderate level of baseline RASs to NS5A-DAAs with marked differences among regions was observed. Close surveillance of response to treatment with DAAs will be important.application/pdfpt_PTEpidemic history and baseline resistance to NS5A-specific direct acting drugs of hepatitis C virus in SpainPersonalPalladino, ClaudiaDSpacehttp://dspace.org/items/96b2385b-89f4-428a-9ab2-6fdb5514541bDSpacehttp://dspace.org/items/96b2385b-89f4-428a-9ab2-6fdb5514541bPalladinoClaudiaCiência IDhttps://www.ciencia-id.pt721D-6851-20D5ORCIDhttp://orcid.org0000-0002-8148-0928PersonalEzeonwumelu, Ifeanyi J.DSpacehttp://dspace.org/items/124ca7f9-fbba-4c7a-a77b-ecda48de1bb0DSpacehttp://dspace.org/items/124ca7f9-fbba-4c7a-a77b-ecda48de1bb0EzeonwumeluIfeanyiORCIDhttp://orcid.org0000-0003-4007-2212Researcher IDhttps://www.researcherid.comP-9428-2017Researcher IDhttps://www.researcherid.comGQP-0394-2022Scopus Author IDhttps://www.scopus.com57203432749PersonalMaté, IreneDSpacehttp://dspace.org/items/3145c0e5-1ca2-4bdf-b103-9e79218b07cdDSpacehttp://dspace.org/items/3145c0e5-1ca2-4bdf-b103-9e79218b07cdMatéIreneORCIDhttp://orcid.org0000-0002-9045-9581PersonalBorrego, PedroDSpacehttp://dspace.org/items/64f9a682-4d1d-4bc3-8854-c6673527f871DSpacehttp://dspace.org/items/64f9a682-4d1d-4bc3-8854-c6673527f871BorregoPedroCiência IDhttps://www.ciencia-id.ptA71C-0177-722FORCIDhttp://orcid.org0000-0002-1949-9484Researcher IDhttps://www.researcherid.comH-6968-2013Scopus Author IDhttps://www.scopus.com25225039400Martínez-Román, PaulaPersonalArca-Lafuente, SoniaDSpacehttp://dspace.org/items/c082ff9e-3d28-42ce-b50a-b23d5a4417a2DSpacehttp://dspace.org/items/c082ff9e-3d28-42ce-b50a-b23d5a4417a2Arca de LafuenteSoniaORCIDhttp://orcid.org0000-0003-4750-0988Researcher IDhttps://www.researcherid.comA-7807-2019PersonalResino, SalvadorDSpacehttp://dspace.org/items/a428ce68-f89c-4f34-af69-04b11f8717caDSpacehttp://dspace.org/items/a428ce68-f89c-4f34-af69-04b11f8717caResinoSalvadorORCIDhttp://orcid.org0000-0001-8783-0450PersonalTaveira, NunoDSpacehttp://dspace.org/items/d62b22f8-7ce6-4bb2-ac55-2117707f6612DSpacehttp://dspace.org/items/d62b22f8-7ce6-4bb2-ac55-2117707f6612TaveiraNunoCiência IDhttps://www.ciencia-id.pt7111-3383-A926ORCIDhttp://orcid.org0000-0003-0176-5585PersonalBriz, VerónicaDSpacehttp://dspace.org/items/4612acdd-e150-40d9-9989-a372cfee3499DSpacehttp://dspace.org/items/4612acdd-e150-40d9-9989-a372cfee3499BrizVerónicaORCIDhttp://orcid.org0000-0003-2297-5098Researcher IDhttps://www.researcherid.comT-4183-2017Scopus Author IDhttps://www.scopus.com9332849600HostingInstitutionOrganizationalRepositório Científico de Acesso Aberto da ULisboae-mailmailto:repositorio@reitoria.ulisboa.ptrepositorio@reitoria.ulisboa.ptDOIIsPartOf10.1038/s41598-020-69692-72023-08-31T13:35:52Z2020-122023-02-03T16:40:01Z2020-12-01T00:00:00ZHandlehttp://hdl.handle.net/10451/59104http://purl.org/coar/access_right/c_abf2open access2260518 bytesliteraturehttp://purl.org/coar/resource_type/c_6501journal article2020-12http://creativecommons.org/licenses/by/4.0/http://purl.org/coar/access_right/c_abf2application/pdffulltexthttps://repositorio.ulisboa.pt/bitstreams/f2090f69-c5e5-4243-8a89-2bb71bb2f816/downloadScientific Reports10113024 |
| spellingShingle | Epidemic history and baseline resistance to NS5A-specific direct acting drugs of hepatitis C virus in Spain Palladino, Claudia |
| status | SINGLETON |
| title | Epidemic history and baseline resistance to NS5A-specific direct acting drugs of hepatitis C virus in Spain |
| title_full | Epidemic history and baseline resistance to NS5A-specific direct acting drugs of hepatitis C virus in Spain |
| title_fullStr | Epidemic history and baseline resistance to NS5A-specific direct acting drugs of hepatitis C virus in Spain |
| title_full_unstemmed | Epidemic history and baseline resistance to NS5A-specific direct acting drugs of hepatitis C virus in Spain |
| title_short | Epidemic history and baseline resistance to NS5A-specific direct acting drugs of hepatitis C virus in Spain |
| title_sort | Epidemic history and baseline resistance to NS5A-specific direct acting drugs of hepatitis C virus in Spain |
| url | http://hdl.handle.net/10451/59104 |
| visible | 1 |